Logo image of AGL

AGILON HEALTH INC (AGL) Stock Fundamental Analysis

NYSE:AGL - New York Stock Exchange, Inc. - US00857U1079 - Common Stock - Currency: USD

4  -1.47 (-26.87%)

After market: 4 0 (0%)

Fundamental Rating

2

Taking everything into account, AGL scores 2 out of 10 in our fundamental rating. AGL was compared to 106 industry peers in the Health Care Providers & Services industry. AGL has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AGL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AGL has reported negative net income.
AGL had a negative operating cash flow in the past year.
AGL had negative earnings in each of the past 5 years.
AGL had a negative operating cash flow in each of the past 5 years.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.00%, AGL is doing worse than 76.42% of the companies in the same industry.
The Return On Equity of AGL (-55.24%) is worse than 71.70% of its industry peers.
Industry RankSector Rank
ROA -15%
ROE -55.24%
ROIC N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AGL's Gross Margin of 3.60% is on the low side compared to the rest of the industry. AGL is outperformed by 81.13% of its industry peers.
AGL's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

3

2. Health

2.1 Basic Checks

AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGL has more shares outstanding
The number of shares outstanding for AGL has been increased compared to 5 years ago.
AGL has a better debt/assets ratio than last year.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.66 indicates that AGL is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.66, AGL is in line with its industry, outperforming 59.43% of the companies in the same industry.
A Debt/Equity ratio of 0.07 indicates that AGL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.07, AGL is in the better half of the industry, outperforming 75.47% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 2.66
ROIC/WACCN/A
WACC9%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.27 indicates that AGL should not have too much problems paying its short term obligations.
AGL has a Current ratio of 1.27. This is in the lower half of the industry: AGL underperforms 60.38% of its industry peers.
A Quick Ratio of 1.27 indicates that AGL should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.27, AGL perfoms like the industry average, outperforming 48.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

6

3. Growth

3.1 Past

AGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.57%.
AGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.41%.
The Revenue has been growing by 50.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.59%
Revenue 1Y (TTM)40.41%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%44.16%

3.2 Future

The Earnings Per Share is expected to grow by 26.11% on average over the next years. This is a very strong growth
AGL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.65% yearly.
EPS Next Y43.49%
EPS Next 2Y28.67%
EPS Next 3Y22.55%
EPS Next 5Y26.11%
Revenue Next Year-2.03%
Revenue Next 2Y4.52%
Revenue Next 3Y8.83%
Revenue Next 5Y10.66%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

AGL's earnings are expected to grow with 22.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.67%
EPS Next 3Y22.55%

More info and screens

0

5. Dividend

5.1 Amount

AGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGILON HEALTH INC

NYSE:AGL (4/17/2025, 8:04:00 PM)

After market: 4 0 (0%)

4

-1.47 (-26.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners77.43%
Inst Owner Change0%
Ins Owners1.81%
Ins Owner Change1.77%
Market Cap1.65B
Analysts63.7
Price Target3.47 (-13.25%)
Short Float %5.52%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-91.86%
Min EPS beat(2)-171.08%
Max EPS beat(2)-12.63%
EPS beat(4)2
Avg EPS beat(4)-37.74%
Min EPS beat(4)-171.08%
Max EPS beat(4)18.64%
EPS beat(8)3
Avg EPS beat(8)-24.94%
EPS beat(12)3
Avg EPS beat(12)-47.86%
EPS beat(16)4
Avg EPS beat(16)-123.73%
Revenue beat(2)0
Avg Revenue beat(2)-1.43%
Min Revenue beat(2)-2.29%
Max Revenue beat(2)-0.56%
Revenue beat(4)0
Avg Revenue beat(4)-2.42%
Min Revenue beat(4)-5.86%
Max Revenue beat(4)-0.56%
Revenue beat(8)4
Avg Revenue beat(8)0.7%
Revenue beat(12)8
Avg Revenue beat(12)1.39%
Revenue beat(16)12
Avg Revenue beat(16)1.5%
PT rev (1m)3.81%
PT rev (3m)27.63%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)85.36%
EPS NY rev (1m)11.79%
EPS NY rev (3m)9.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-13.14%
Revenue NY rev (1m)-3.2%
Revenue NY rev (3m)-10.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.27
P/FCF N/A
P/OCF N/A
P/B 3.5
P/tB 4.41
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS14.7
BVpS1.14
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15%
ROE -55.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.6%
FCFM N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
F-Score3
Asset Turnover3.5
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 168.77%
Cap/Sales 0.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 2.66
F-Score3
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)186.26%
Cap/Depr(5y)133.4%
Cap/Sales(3y)0.87%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.59%
EPS Next Y43.49%
EPS Next 2Y28.67%
EPS Next 3Y22.55%
EPS Next 5Y26.11%
Revenue 1Y (TTM)40.41%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%44.16%
Revenue Next Year-2.03%
Revenue Next 2Y4.52%
Revenue Next 3Y8.83%
Revenue Next 5Y10.66%
EBIT growth 1Y-24.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.55%
EBIT Next 3Y28.85%
EBIT Next 5Y19.01%
FCF growth 1Y47.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.01%
OCF growth 3YN/A
OCF growth 5YN/A